NCT03044613View on ClinicalTrials.gov

Nivolumab +/- Relatlimab Prior to Chemoradiation With II/III Gastro/Esophageal Cancer

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

July 11, 2017

Primary Completion Date

March 31, 2027

Study Completion Date

August 31, 2027

Conditions
Gastric CancerEsophageal CancerGastroEsophageal Cancer
Interventions
DRUG

Nivolumab

240mg or 1 mg/kg administered IV

DRUG

Relatlimab

80mg administered IV

DRUG

Carboplatin

standard care dose

DRUG

Paclitaxel

standard care dose

RADIATION

Radiation

standard care dose

Trial Locations (3)

15212

Alleghany Health Network, Pittsburgh

21287

Johns Hopkins University, Baltimore

75246

Baylor University/ Charles A. Sammons Cancer Center, Dallas

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER